Guest User 10/15/20 Guest User 10/15/20

Immune-Onc Therapeutics Announces SITC Poster Presentation on IO-108, a Novel Cancer Immunotherapy Targeting LILRB2 (ILT4) for Solid Tumors

Guest User 9/16/20 Guest User 9/16/20

Immune-Onc Therapeutics Announces First Patient Dosed in Phase I Trial Evaluating IO-202, a First-In-Class Antibody for the Treatment of Acute Myeloid Leukemia

Guest User 8/4/20 Guest User 8/4/20

Immune-Onc Therapeutics Awarded $2.14 Million National Cancer Institute SBIR Grant to Support Development of IO-202, a First-in-Class Antibody Targeting LILRB4

Guest User 5/29/20 Guest User 5/29/20

Acute Myeloid Leukemia: Background for Media

Guest User 5/29/20 Guest User 5/29/20

Immune-Onc Therapeutics IND Application for First-In-Human Trial of IO-202, a Novel Antibody for the Treatment of Acute Myeloid Leukemia, Receives FDA Clearance

Guest User 11/19/19 Guest User 11/19/19

Immune-Onc Therapeutics Prepares for its Next Phase of Growth with New Leadership Appointments and Key Board Member Additions

Guest User 10/17/18 Guest User 10/17/18

Immune-Onc Therapeutics and University of Texas Report a Novel Target for Acute Myeloid Leukemia in Nature

Guest User 9/18/18 Guest User 9/18/18

Immune-Onc Therapeutics Announces Key Executive Appointments and Series B Funding

Guest User 10/12/17 Guest User 10/12/17

Immune-Onc Therapeutics, Inc. Awarded “Buzz of BIO”

Guest User 6/28/17 Guest User 6/28/17

Immune-Onc Therapeutics, Inc. Selected to Join the Prestigious Stanford-backed StartX Community

Guest User 4/6/17 Guest User 4/6/17

Immune-Onc Therapeutics, Inc. Announces Partnership with University of Texas to Develop Novel Cancer Immunotherapy

Guest User 3/28/17 Guest User 3/28/17

Immune-Onc Therapeutics, Inc. Announces Licensing and Collaboration with Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center to Develop Novel Cancer Immunotherapy

Guest User 9/1/16 Guest User 9/1/16

Immune-Onc Therapeutics, Inc. Announces $7 Million Series A Financing